Similar articles for PMID: 29049402

Year	Number of Results
2000	1
2001	1
2002	1
2003	2
2004	2
2005	2
2006	3
2007	1
2008	1
2009	6
2010	1
2011	5
2012	7
2013	5
2014	11
2015	9
2016	7
2017	9
2018	5
2019	6
2020	9
2021	2
2022	7
2023	1
2024	0

1

Upward trends of acquired drug resistances in Ethiopian HIV-1C isolates: A decade longitudinal study.

Mulu A, Maier M, Liebert UG. Mulu A, et al. PLoS One. 2017 Oct 19;12(10):e0186619. doi: 10.1371/journal.pone.0186619. eCollection 2017. PLoS One. 2017. PMID: 29049402 Free PMC article.

2

Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.

Mulu A, Maier M, Liebert UG. Mulu A, et al. PLoS One. 2015 Oct 29;10(10):e0141318. doi: 10.1371/journal.pone.0141318. eCollection 2015. PLoS One. 2015. PMID: 26512902 Free PMC article.

3

Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.

Barth RE, Aitken SC, Tempelman H, Geelen SP, van Bussel EM, Hoepelman AI, Schuurman R, Wensing AM. Barth RE, et al. Antivir Ther. 2012;17(2):377-86. doi: 10.3851/IMP2010. Epub 2011 Dec 2. Antivir Ther. 2012. PMID: 22297391

4

Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.

Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondoa P, Wellington M, Siwale M, Nankya I, Kaudha E, Akanmu AS, Botes ME, Steegen K, Calis JC, Rinke de Wit TF, Sigaloff KC. Boender TS, et al. J Antimicrob Chemother. 2016 Oct;71(10):2918-27. doi: 10.1093/jac/dkw218. Epub 2016 Jun 23. J Antimicrob Chemother. 2016. PMID: 27342546

5

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K. Van Vaerenbergh K. Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.

6

Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.

Svärd J, Mugusi S, Mloka D, Neogi U, Meini G, Mugusi F, Incardona F, Zazzi M, Sönnerborg A. Svärd J, et al. PLoS One. 2017 Jun 5;12(6):e0178942. doi: 10.1371/journal.pone.0178942. eCollection 2017. PLoS One. 2017. PMID: 28582463 Free PMC article.

7

Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania.

Mziray SR, Kumburu HH, Assey HB, Sonda TB, Mahande MJ, Msuya SE, Kiwelu IE. Mziray SR, et al. PLoS One. 2020 Sep 28;15(9):e0232649. doi: 10.1371/journal.pone.0232649. eCollection 2020. PLoS One. 2020. PMID: 32986709 Free PMC article.

8

A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort.

Telele NF, Kalu AW, Gebre-Selassie S, Fekade D, Marrone G, Grossmann S, Neogi U, Tegbaru B, Sönnerborg A. Telele NF, et al. BMC Infect Dis. 2019 Jul 1;19(1):569. doi: 10.1186/s12879-019-4196-8. BMC Infect Dis. 2019. PMID: 31262272 Free PMC article.

9

HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.

Ait-Khaled M, Rakik A, Griffin P, Stone C, Richards N, Thomas D, Falloon J, Tisdale M; CNA2007 International Study Team. Ait-Khaled M, et al. Antivir Ther. 2003 Apr;8(2):111-20. Antivir Ther. 2003. PMID: 12741623 Clinical Trial.

10

Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa.

Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER). Sigaloff KC, et al. J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):23-31. doi: 10.1097/QAI.0b013e318227fc34. J Acquir Immune Defic Syndr. 2011. PMID: 21694603 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

96 results

Results by year